Abstract
Phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) are new antimitotic prodrugs bioactivated by the enzyme CYP1A1 into phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates (PIB-SOs) that are potently (nM) and selectively inhibiting the growth of CYP1A1-expressing breast cancer cells. The screening program identified three PAIB-SOs designated as CEU-835, CEU-934, and CEU-938 for further pharmacokinetic studies. A novel method for their quantification in CD-1® IGS female mouse plasma using a Waters UHPLC ACQUITY Arc system was developed and validated. Their analytical measurements ranged from 7.3 to 1484 ng/mL. They exhibited linearity between 7.3 and 1484 ng/mL. They also showed good resolutions (2.21–4.99) and good theoretical plate numbers (14707–70580). Moreover, they were robust at wavelengths between 273 and 310 nm and sensitive from 2 to 62 AU/ng mL−1. This new method is indispensable to assess PAIB-SOs half-life in mouse plasma and for the quantification of PAIB-SOs in other biological matrices.
Similar content being viewed by others
REFERENCES
Smolarz, B., Nowak, A.Z., and Romanowicz, H., Cancers, 2022, vol. 14, no. 10, p. 2569.
Fortin, S., Charest-Morin, X., Turcotte, V., Lauvaux, C., Lacroix, J., Cote, M.-F., Gobeil, S., and C.-Gaudreault, R., J. Med. Chem., 2017, vol. 60, no. 12, p. 4963.
Zarifi Khosroshahi, M., Chavez Alvarez, A.C., Gagne-Boulet, M., C.-Gaudreault, R., Gobeil, S., and Fortin, S., J. Pharm. Pharmacol., 2020, vol. 72, no. 2, p. 249.
Bouzriba, C., Chavez Alvarez, A.C., Gagne-Boulet, M., Ouellette, V., Lacroix, J., Côté, M.-F., C.-Gaudreault, R., and Fortin, S., Eur. J. Med. Chem., 2021, vol. 229, p. 114003.
Chavez Alvarez, A.C., Bouzriba, C., Moreau, E., Auzeloux, P., Besse, S., Ouellette, V., Zarifi Khosroshahi, M., Côté, M.-F., Pilote, S., Miot-Noirault, E., Chezal, J.-M., Simard, C., C.-Gaudreault, R., and Fortin, S., J. Med. Chem., 2023, vol. 66, no. 4, p. 2477.
Fortin, S., Wei, L., Moreau, E., Lacroix, J., Côté, M.F., Petitclerc, E., P. Kotra, L., and C.-Gaudreault, R., Eur. J. Med. Chem., 2011, vol. 46, no. 11, p. 5327.
Fortin, S., Wei, L., Moreau, E., Lacroix, J., Côté, M.-F., Petitclerc, E., P. Kotra, L., and C.-Gaudreault, R., J. Med. Chem., 2011, vol. 54, no. 13, p. 4559.
Panchagnula, R. and Thomas, N.S., Int. J. Pharm., 2000, vol. 201, no. 2, p. 131.
Jang, G.R., Harris, R.Z., and Lau, D.T., Med. Res. Rev., 2001, vol. 21, no. 5, p. 382.
Manikandan, S., J. Pharmacol. Pharmacother., 2011, vol. 2, no. 2, p. 140.
Lee, D.K., In, J., and Lee, S., Korean J. Anesthesiol., 2015, vol. 68, no. 3, p. 220.
Taylor, J.K., Anal. Chem., 1981, vol. 53, no. 14, p. 1588A.
Papadoyannis, I.N. and Samanidou, V.F., J. Liq. Chromatogr. Relat. Technol., 2004, vol. 27, no. 5, p. 753.
Doran, P.M., Unit operations, in Bioprocess Engineering Principles, Doran, P.M., Ed., London: Academic, 1995, p. 218.
ACKNOWLEDGEMENTS
The authors would like to thank Dr. Alexandre Patenaude for his assistance in the correction of the manuscript.
Funding
This research was supported by grants from Fonds de Recherche du Québec-Santé (FRQ-S), research infrastructure program of John R. Evans Leaders Fund from Canada Foundation for Innovation (CFI, Canada, grant No. 36231), Fonds d’enseignement et de recherche of the Faculté de pharmacie de l’Université Laval, Réseau québécois de recherche sur les médicaments (RQRM) and Canadian Institutes of Health Research (PJT-178096). A.C. Chavez Alvarez, C. Bouzriba, V. Ouellette and M. Gagné-Boulet are recipients of studentships from the Fonds d’enseignement et de recherche of the Faculté de pharmacie de l’Université Laval and FRQ-S. S. Fortin is the recipient of a Junior 2 research scholar award from FRQ-S.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Animal-related experiments were conducted in accordance with the Conseil canadien de protection des animaux (CCPA) and the Comité de protection des animaux de l’Université Laval (CPAUL) and its guidelines (https://www.services-recherche.ulaval.ca/conduite-responsable-et-ethique/protection-des-animaux). Animal protocols were approved by the CPAUL, Université Laval, Québec, Canada (Approval IDs 2018-014-1 and 2018-014-2).
CONFLICT OF INTEREST
The authors of this work declare that they have no conflicts of interest.
Additional information
Publisher’s Note.
Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alvarez, A., Bouzriba, C., Bernier, L. et al. Development of an UHPLC-UV Method for Quantification of Three Phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates in CD-1® IGS Female Mouse Plasma. J Anal Chem 79, 456–463 (2024). https://doi.org/10.1134/S1061934824040026
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1061934824040026